Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.37 |
| ▸ | FAP | Q12884 | 7/20 | 0.37 |
| ▸ | PITRM1 | Q5JRX3 | 4/20 | 0.37 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4731041 | 0.82 | DPP4 (0.35) | DPP4GRIN2BGRIN2C | |
| SCHEMBL4730897 | 0.82 | DPP4 (0.35) | DPP4GRIN2BGRIN2C | |
| SCHEMBL19431086 | 0.78 | DPP4 (0.32) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL10202116 | 0.75 | DPP4 (0.53) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL18923070 | 0.75 | CTSL (0.39) | PREP | |
| SCHEMBL4730150 | 0.75 | CTSL (0.39) | PREP | |
| SCHEMBL4743897 | 0.75 | CTSL (0.39) | PREP | |
| SCHEMBL4728726 | 0.75 | CTSL (0.39) | PREP | |
| SCHEMBL1632220 | 0.74 | FFAR3 (0.30) | — | |
| SCHEMBL4728395 | 0.74 | CYP3A4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260414-B2 | Inhibitors of hepatitic C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260414-B2 | Inhibitors of hepatitic C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | HAVCR2, SLC10A1, HDGF | DPP4 405/4885DPP7 362/4885DPP8 725/4885 |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, ZC3HAV1 | DPP4 475/4885DPP7 420/4885DPP8 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.